Last reviewed · How we verify
NCT02653833
The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy
EARLY_PHASE1 trial testing Tadalafil 20 MG in Muscular Dystrophy in 6 participants. Terminated before completion.
1 September 2018
Quick facts
| Lead sponsor | Cedars-Sinai Medical Center |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 6 |
| Start date | 1 November 2017 |
| Primary completion | 1 September 2018 |
| Estimated completion | 1 September 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Tadalafil 20 MG — full drug profile →
- beetroot juice extract
Conditions studied
- Muscular Dystrophy — all drugs for Muscular Dystrophy →
Sponsor
Cedars-Sinai Medical Center
Who can join
Adults 18 to 45, male only, with Muscular Dystrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This pilot study tests the hypothesis that the medication nitric oxide extract from beetroot juice improves blood flow to the skeletal muscle during exercise. The investigators will use cutting edge technology with contrast enhanced ultrasound to visualize the microvascular blood supply to the forearm. Animal studies have shown reversal of muscle damage with improved delivery of blood to the exercising muscle. This research aims to understand the mechanism of action of this medication in a way it has never been studied before. The results may help benefit individuals with muscular Dystrophy in the future.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02653833
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tadalafil 20 MG
Trials testing the same drug.
- NCT05709574 — Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer · Phase 2 · recruiting
- NCT04684589 — Effect of PDE5 Inhibition on Adipose Metabolism in Humans · Phase 2 · completed
- NCT04164355 — Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg · completed
- NCT04491773 — Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg for More Than 6 Months · completed
- NCT03905018 — Effect of Tadalafil Administration on Vasodilatation Mediated by Flow in Patients With Obesity Grade I-II · Phase 3 · unknown
Other recruiting trials for Muscular Dystrophy
Currently open trials in the same condition.
- NCT07321977 — Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular D · NA · recruiting
- NCT05726591 — Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Dis · NA · recruiting
- NCT05237973 — Investigational Use of Neuromuscular Ultrasound · recruiting
- NCT04038138 — Clinical Trial Readiness Network FSHD France: Prospective 24 Months MRI Study · NA · active not recruiting
- NCT00004568 — Study of Inherited Neurological Disorders · recruiting
Other Cedars-Sinai Medical Center trials
Trials by the same sponsor.
- NCT06012487 — Correlates and Control of Blood Pressure Variability · Phase 1 · not yet recruiting
- NCT07495995 — SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis · Phase 2 · not yet recruiting
- NCT07413965 — TAVR vs SAVR in Severe Bicuspid Aortic Stenosis · NA · not yet recruiting
- NCT06521021 — CHOICE to AVOID or RESIST · NA · not yet recruiting
- NCT07499089 — Together-Breast Cancer Support Platform · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02653833 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cedars-Sinai Medical Center
- Last refreshed: 14 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02653833.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing